The giant leap forward in virtual health is punctuating the need for reliable, clinically accurate technologies to advance how virtual medicine is delivered.
During product development, collaboration between software, hardware and quality teams must be tracked and seamless to meet the increasing pace of market demand.
This year’s virtual event features experts from medical device companies, hospitals and government organizations.
Medtech companies will need to collaborate more closely with other parties in healthcare, as the aftermath of the coronavirus pandemic will have a comprehensive reach throughout the entire ecosystem. MTI speaks with Johnson & Johnson VP Raymond Fryrear, M.D. on the topic.
Medical device companies are committing significant resources to the fight against Covid-19. Collaboration tools can help expedite product design while supporting evolving compliance standards.
Whatever the short- and longer-term fallout of COVID-19, organizations will need to come back fighting—with new tools at their disposal and ready to raise their game.
Recalls for failure are chronic in the medical device industry. The sources of those failures could originate anywhere in the supply chain. Fixing supply chain issues is ultimately the responsibility of the instrument’s maker.
The latest regulations for human and veterinary medicinal products, as well as medical devices, include the mandate to set up databases with detailed information about available products. These databases must be realized and implemented in the near future, and require a concerted effort now if tangible real-world benefits are to follow.
Across the continent, governments and hospitals are purchasing robotics systems from abroad as well as developing the technologies themselves.
Medtech manufacturers must continue to embrace collaboration and transparency.